welcome to the future of human optimization

January 8, 2021 Legal Disclaimer in thispresentation shouldnotbe unduly relied uponby investors. opinions, estimates, and assumptions willprove to becorrect. The forward-looking statements included looking statements; however, noassurance canbegiven that theseexpectations andtheunderlying com. The Company believes there isareasonable basisfor theexpectations reflected intheforward- customer demand;andotherssetoutintheCompany’s preliminary prospectus available at www.sedar. technology security;cashavailable to fundoperations; crop risk;availability ofcapital;changesin acceptance andcompeting products; internet andsystem infrastructure functionality;information unemployment rates ontheCompany’s stakeholders; general economic andfinancial conditions; product the broader market for andcustomers oftheCompany’s products; the impact ofglobalconditions and impact oftheCOVID-19 pandemicto theCompany’s operations, supplychain,distribution chainandto certain crop yields; product liability;government regulation; theCompany’s expansion plans;theadverse statements, including,amongothers,theCompany’s partnershipwithlicense holdersthat project could causeactualevents orresults to differ materially from thoseanticipated intheforward-looking statements are made, andare subjectto avariety ofrisksanduncertainties andotherfactors that Forward-looking statements are basedontheopinionsandestimates ofmanagementat thedate the statements. may causeactualresults orevents to differ materially from thoseanticipated insuchforward-looking These statements involve known and unknown risks,assumptions, uncertainties, andotherfactors that the Company’s business andfinancial condition, anticipated product category growth, andonlinesales. may besold,expansion oftheCompany’s distribution channels,theimpactofstrategic partnerships on sales ofmushroom derived products, expansion ofplatforms through whichtheCompany’s products of theOffering andOptimi’s plans,focus andobjectives, theCompany’s assessment of, andtargets for, of theOffering, completion oftheOffering, theanticipated Offering Price, theuseofnetproceeds pertaining to theCompany’s proposed business involving psilocybin, theproposed CSElisting, thesize forward-looking statements. Examples offorward-looking statements include, amongothers,statements “estimated”, “intends”, “plans”, “projection”, “outlook” andsimilarexpressions are intended to identify “should”, “believe”, “willlikely result”, “are expected to”, “willcontinue”, “isanticipated”, “believes”, “estimate”, “expect”, “may”, “will”,“project”, “predict”, “potential”, “targeting”, “intend”, “could”, “might”, looking statements. The use ofany words orphrases suchas“seek,” “anticipate”, “plan”,“continue”, conditions andcourses ofaction.Allstatements otherthanstatements ofhistorical fact are forward- to possible events, conditions orfinancial performance oftheCompany basedonfuture economic looking information (collectively, “forward-looking statements”). Suchforward-looking statements relate Certain statements contained inthispresentation constitute forward-looking statements andforward- Forward-Looking Information strictly prohibited. or to any personorinany mediumwhatsoever. Any unauthorized useofthepresentation is provided herein, thispresentation may notbecopied orotherwisedistributed, inwholeorpart,by not authorized anyone to provide prospective purchasers withthispresentation. Except asspecifically Capital Corporation, Canaccord CapitalCorporation andStifel Nicolaus CanadaInc.(the“Agents”) have information contained inthispresentation to theexclusion ofothers.The Company andMackieResearch information contained intheProspectus. Aprospective investor isnotentitledto rely onpartsofthe This presentation isqualified initsentirety by reference to, andmust beread inconjunction with,the of Optimi.HealthCorp. (the“Company” or“Optimi”)dated December 28,2020 (the“Prospectus”). Prospective investors shouldrely onlyontheinformation contained in thepreliminary prospectus issue, orthesolicitation ofanover to issue, securitiesofOptimiorotherfinancial products. “Company”) for informational purposesonlyanddoesnotconstitute anoffer to issue orarrange to The information contained inthispresentation isprovided by OptimiHealthCorp. (“Optimi”orthe under theSecurities Act. We seeksafe harbor. which suchanoffer would beillegal.The Company’s securitieshave notbeenandwillberegistered United States SecuritiesAct of1933, asamended(the“Securities Act”) orinany otherjurisdiction in that is,orisactingfor theaccount orbenefit of, any U.S. personasdefined inRegulation Sunderthe This presentation does not constitute anoffer ofshares for saleintheUnited States or to any person Safe Harbor distributed to you inelectronic format and thehard copy version that may bemadeavailable to you. accepts any liabilityorresponsibility whatsoever inrespect ofany difference between thedocument Company norany director, officer, employee oragentofany ofthemorany affiliate ofany suchperson it isfree from virusesand otheritems ofadestructive nature. Asaconsequence oftheabove, neitherthe electronic transmission isat your own riskanditisyour responsibility to take precautions to ensure that You are responsible for protecting against virusesandotherdestructive items. Your receipt ofthis transmitted viathismediummay bealtered orchangedduringtheprocess ofelectronic transmission. This presentation may have beensentto you inanelectronic form. You are reminded that documents Electronic Form exact oraddconsistently dueto rounding. representation asto theaccuracy ofsuchinformation. Somenumbersinthispresentation may notbe ascertained theunderlyingassumptions relied uponby suchsources. The Company doesnotmake any presentation oranalyzed orverified theunderlying reports relied uponorreferred to by suchsources, or the Company hasnotindependently verified any ofthedata from third- partysources referred to inthis and othersources believed by theCompany to betrue. AlthoughtheCompany believes itto bereliable, This presentation includesmarket andindustry data obtainedfrom various publiclyavailable sources Third-Party Information Mackie Research CapitalCorp., Canaccord GenuityCorp. orStifel Nicolaus CanadaInc. delivered withthisdocument.Copies oftheprospectus may beobtainedfrom (i)www.sedar.com or(ii) before makinganinvestment decision.Acopy oftheprospectus, andany amendments,isrequired to be any amendmentfor disclosure ofthosefacts, especiallyriskfactors relating to thesecuritiesoffered, to thesecuritiesoffered. Investors shouldread thepreliminary prospectus, thefinal prospectus and prospectus hasbeenissued. This documentdoesnotprovide fulldisclosure ofallmaterial facts relating There willnotbeany saleorany acceptance ofanoffer to buythesecuritiesuntilareceipt for thefinal is required to bedelivered withthisdocument.The preliminary prospectus isstill subjectto completion. the provinces ofCanada,excluding Quebec. Acopy ofthepreliminary prospectus, andany amendment, securities describedinthisdocumenthasbeenfiled withthesecuritiesregulatory authoritiesineachof analyzing theCompany. Apreliminary prospectus containing importantinformation relating to the tax andotheradvisorssuchfactors that they consider appropriate ininvestigating and Without limitation, prospective investors shouldconsider theadvice oftheirfinancial, legal,accounting, their own analyses andreviews oftheCompany andofthe information contained inthispresentation. information that aprospective investor may require. Prospective investors are encouraged to conduct The information contained inthispresentation doesnotpurportto beallinclusive orto contain all Reference to Prospectus information, future events orotherwise, except asrequired by applicablelaw. looking statements, orthefactors orassumptions underlyingthem,whetherasaresult ofnew Company expressly disclaimsany obligation to update oralter statements containing any forward- the date ofthispresentation andare expressly qualified by theforegoing cautionarystatements. The All oftheforward-looking statements andinformation contained inthispresentation speakonlyasof Investor Deck2021 2 Highlights Optimi proprietary IP multipleclinical trialswith withaUniversity partnerto run • SignedPartnership Agreement willbe100%owned by Optimi Dealerto develop IP(resulting IP • SignedAgreement withLicensed B2Brelationships opportunitiesthrough established • International salesandgrowth &completed buildingshells assets: E-Commerce, Two permitted • Potential multi-revenue generating Cultivation to Consumer (CTC) • Vertically integrated operation: ADVANTAGES BUSINESS STRATEGIC

STRATEGIC permitted &zoned for use • Expansionopportunity:+25acres construction. &EUGMP-capablefacilities under • Two 10,000 sq.ft.(each) GMP Psilocybin Cultivation License Application for large scale • Submitted HealthCanadaDealers • In-houseHealthCanadaconsulting FACILITIES CULTIVATION EXCEPTIONAL

WORLD CLASS cannabisfacility onadjacent property completed, HealthCanadaapproved, • Experienced team operates arecently supplementretailer Direct To Consumer (DTC) Canada’s biggest online • Agreement to work with distribution, wholesale, andretail incultivation, finance, nutraceutical • Experienced Managementteam key aspectsofthebusiness • Strong Advisory Team supportingall TEAM & PASSIONATE EXPERIENCED

PASSIONATE pipelineofpartners programs plannedwithastrong • Turn-key influencer marketing marketplace, immediate revenue • Earlyentryinto rapidly expanding Q12021 manufactured &tested -launching • Supplementlinehasbeen first 7product offerings • Submitted NPNapplications for CTC OPPORTUNITY NUTRACEUTICALS PREMIUM Investor Deck2021

3 PREMIUM transforming identity through human optimization

Optimi Health believes that personal identity is a fl uid and evolving aspect of all our lives and encompasses our physical, spiritual and mental well-being. Why Mushrooms? GLOBALLY $ GROWTH $ ANNUAL MARKET MARKET SHARE 34B 6% 18B * NUTRACEUTICALS MARKET SHAREFROM OF THEGLOBAL WITH $18BILLION BY 2025 BILLION GLOBALLY FORECAST TO $34 IS GROWING MUSHROOM MARKET FUNCTIONAL THE GLOBAL *Select Data Sources: Verifiedmarketresearch.com and ResearchAndMarkets.com market demand. consumer trends whichdrive highly valued ingredients focused on products willencompass aspectrumof using Optimi-farmed ortarget sourced high qualityproduction. Supplements research helpOptimistreamline Advanced expertise andongoing popular functionalmushrooms. Cordyceps extracts are themost Chaga, Reishi, Lion’s Maneand that drive theMarket Functional Mushrooms Investor Deck2021 5 The Functional Mushroom and Mushroom Nutraceutical blends are Market is Growing simply more appealing. Why Now? The global functional mushroom market is Blends have a higher average cost per serving growing at 6% annually, netting to $34B compared to pure mushroom products. globally by 2025 with $18B of the market Growing a variety of mushrooms can be share from nutraceuticals (not including benefi cial in developing locally grown custom alternative uses for mycelium). Interest blended mushroom formulations. Customers in functional mushrooms continues to appreciate and pay more for blends as they grow globally for all forms (fresh, extracts, provide a wider variety of benefi ts. Offering mycelium, and fruiting bodies). Customers blends positions Optimi to realize higher are highly interested in mushroom-focused retail price per serving. nutraceutical products, with over 50% of the overall functional mushroom market attributed to nutraceuticals.

Investor Deck 2021 6 Bryan Safarik Jacob Safarik Mike Stier COO & DIRECTOR CFO CEO & DIRECTOR

Over fi fteen years of experience in Senior Over 12 years of experience in accounting, Following Mike’s studies in business Management roles, as well as Founder project fi nance, business development management & fi nance at Kwantlen University, and President of various profi table private and quality assurance. Jacob graduated he worked for CIBC as a licensed Senior companies. Bryan’s experience includes from McGill University with a Bachelor Financial Advisor managing assets over 100m. developing operational effi ciencies at Ocean of Commerce degree and is a Chartered Mike specializes in M&A, corporate fi nance, Our Team Fisheries LTD before serving as Director of Professional Accountant. Prior experience and currently sits as President & CEO of New Marine Operations prior to the sale to the includes playing a pivotal advisory role in the Leaf Ventures (CSE). Jim Pattison group. After assisting with the sale of a $6 billion business in San Francisco. successful sale of Ocean’s, Bryan co-founded, Jacob also worked in Vienna, Austria and currently serves as President for BC where he managed various consulting and Green Pharmaceuticals Inc. Bryan received assurance engagements for the European a Bachelors of Science degree from Union. Jacob is also a cofounder of BC Green Wingate University. Pharmaceuticals Inc and currently serves as their Chief Financial Offi cer.

JJ Wilson Dane Stevens Jon Schintler CHAIRMAN OF THE BOARD CMO & DIRECTOR INDEPENDENT DIRECTOR

Active CEO and Co-Founder of Ride Cycle An entrepreneur with 12 years experience in Jon is an accomplished senior leader, Club and Partner at Very Polite Agency. JJ’s international product sourcing, development, manager, developer and capital markets previous experience includes leading the manufacturing, and quality control, Dane is professional with a demonstrated track record international expansion of Kit and Ace, in the founder of multiple successful wholesale spanning 15 years in the clean energy space. addition to developing the businesses brand, and retail DTC businesses, and is currently He is experienced in providing strategic ecommerce, and retail. A recent graduate President of Cavalier Jewellers LTD. After leadership to organizations and C-level from Harvard Business School, JJ now investing in several venture start-ups, Dane management. Extensive greenfi eld and M&A focuses on strategic growth initiatives and now concentrates his efforts on various work on developing, fi nancing, and managing development for his operating companies, in philanthropic endeavours, and on the science- utility scale wind, solar, run-of-river hydro, addition to independent strategic investments, based benefi ts in the rapidly evolving world thermal and geothermal energy projects and philanthropy. of fungi. totaling more than 2.5 GWs.

Investor Deck 2021 7 Chip Wilson Edward Safarik Harley Pasternak ADVISOR ADVISOR ADVISOR

Chip Wilson is a Canadian businessman Edward is a Member in good standing of As a fi tness and nutrition specialist, and philanthropist, who has founded the Law Society of British Columbia and Mr. Pasternak’s client roster includes Ariana several retail apparel companies, most former Founder, President and CEO of Ocean Grande, , , Kim Kardashian, notably yoga-inspired athletic apparel Fisheries Limited. Edward offers extensive , Katy Perry, , Robert company Lululemon Athletica. Wilson is past board experience: six year board member Downey Jr., , , widely considered to be the creator of the of Genome BC, Chairman of the Fisheries Jessica Simpson, Charlie Puth, , athleisure trend. In 2016, he organized his Counsel of Canada, Cochair of the Food Ke$ha, Hilary Duff and . He personal and business interests into the Agriculture/Fisheries Initiative on Sustainable currently stars on the E! channel’s Revenge

Our Advisors holding company Hold It All Inc. Economic Fisheries, Founder and Chairman of Body with Khloe Kardashian, makes regular the Herring Conservation & Research Society appearances as a fi tness contributor to good of BC (HCRS), and a member of the Pacifi c morning America on ABC, and formerly Scientifi c Advice Review Committee (PSARC) starred on ABC’s The Revolution, and as a and the Herring Industry Advisory judge on Top Model. Mr. Pasternak has made Board (HIAB). worldwide speaking appearances in over 30 countries and is a bestselling fi tness and diet author published in 14 languages in over 25 countries. He holds a Master of Science in Exercise Physiology and Nutritional Sciences from the and an Honors Elfi Daniel-Ivad Leigh Grant Degree in Kinesiology from University of LICENSING ADVISOR FACILITY ADVISOR Western Ontario. He is also certifi ed by The American College of Sports Medicine and The Elfi formally served as Head of Submissions, Over 20 years experience in the HVAC Canadian Society of Exercise Physiology, and Regulatory at Eurofi ns Experchem industry and indoor cannabis cultivation, Leigh served as an exercise and nutrition scientist Laboratories Inc. In this role, she led a specializes in the development of advanced for Canada’s Department of National Defense. team of regulatory professionals in the indoor horticulture systems, for federally development of regulatory submission licensed cannabis producers. Acknowledged strategies for Natural Health Products as an indoor horticulture facility design expert, (NHPs), OTC drugs, cosmetics, medical Leigh consulted for Broken Coast Cannabis, devices, food products, site licenses, from inception to its latest expansions under medical establishment licenses and the Aphria ownership group, and BC Green applicants to become licensed producers Pharmaceuticals. and dealers of federally controlled substances.

Investor Deck 2021 8 Limited Differentiated Better Competition to Products: Extraction Grow Fruiting Processes: Bodies: Almost no competitors Fruiting Bodies offer higher Throughout the industry alcohol currently growing and selling purity and net 35% higher and hot water extraction fruiting bodies in Canada. higher average revenue per processes are most . Optimi aims to position itself serving. While more costly, Because Optimi invests in as the pre-emptive grower farming fruiting bodies fundamental research, advanced of fruiting body mushrooms positions Optimi to offer extraction processes and in North America. Optimi a differentiated product. related production techniques The Industry & Optimi Industry The brand positioning as “Grown While not the leading factor, are being introduced. Since in Canada” targets consumer customers pay more for customers do not differentiate facing differentiation in fruiting body based products. based on extraction processes, the high growth Research heavily favors consideration for cost-effective nutraceutical market. fruiting body based products solutions delivering the highest given their increased potency. returns are achieved when aimed at reducing the $ per serving to the consumer.

Investor Deck 2021 9 Nutraceutical Products of years. fungus inAsiafor thousands and hasbeenusedasamedicinal called thekingofmedicinalfungi protector andfighter. Chagais often The Defense capsulesare your CAPSULE DEFENSE MUSHROOM get anedge. performance individualslookingto Lion’s Maneisusedby high CAPSULE MINDFUL MUSHROOM performance inmind. with your betterment andpeak created theOptimi Formulation your day-to-day performance. We mushrooms formulated to optimize A proprietary blendof5functional Meet your dailymushroom complex. CAPSULES OPTIMI FORMULATION its own. put thismushroom inaleagueof world. Yet, itsincredible benefits commonly found mushrooms inthe Turkey Tail isoneofthemost CAPSULE IMMUNITY MUSHROOM and immunesupport. replenish andprovide antioxidant The Perform capsules are here to that use insects as a host to flourish. Wild cordyceps isaparasitic fungus CAPSULE PERFORM MUSHROOM help promote longevity andwellbeing. over 2,000 years by eastern societiesto of immortality,” Reishi hasbeenusedfor “Queen ofmushrooms” and“mushroom repair andrecharge. Known asthe The Longevity capsulesare here to CAPSULE LONGEVITY MUSHROOM performance inmind. betterment andpeak Formulation withyour Optimi Vegan Protein thriving. We created the will keep you fueledand functional mushrooms stack ofnutritionand powder. This perfect delicious vegan protein mushrooms witha of five functional proprietary blend we’ve combined our human optimization, Designed for maximum VEGAN PROTEIN LIMITLESS Optimi Products for anOptimized Lifestyle Investor Deck2021 10 Functional Ingredients Optimi Health’s highly sought-after range offungivarieties includes: isolation, ortogether for anholistic approach to wellness. popularity, eachwithclinically proven benefits that canbeusedin There are 5mushrooms in particularthat are gainingsignificant • Antioxidant • ImmuneSupport LIONS MANE Medicineto fortify the spleen • UsedinTraditional Chinese • ImmuneSupport TURKEY TAIL • Adaptogen • Antioxidant • ImmuneSupport REISHI • ImmuneSupport andkidneys Medicineto helpreplenish lungs • UsedinTraditional Chinese • Antioxidant • ImmuneSupport CHAGA CORDYCEPS optimal humanperformance. products aimedat kickstarting propietary nutraceutical lineup ofuniquelyCanadian varieties aimto deliver a Our popularandproven quality, natural plant-basedproducts. opimization through consumption ofhigh consumers looking to prioritize personal health &wellness sector andto serve meet theneedsofrapidly expanding Optimi Healthispositioningitselfto Investor Deck2021 11 The Future Psilocybin Products: Pharmaceutical Grade for itsongoing facility build-out. ability into anextensive business planfor research capability, andscalableproduction built-in thesuperior cultivation, advanced Optimi Healthhas already designed and Health Canadafor clinicaltrials. not ableto meetthequalitystandards setby psilocybin isnotreadily available andwill Current production oflegalGMPquality receipt ofadealerslicense. psilocybin for Stage 2&3clinicaltrials upon as alarge scalesupplierofGMP-grade Optimi aimsto strategically positionitself patient baseto runclinicaltrials. has immediate access to alarge, andlegal, Through theresearch partnership, Optimi Wellness (Future) Medicinal (Current) with highqualityproducts (wholesale) SUPPLY OTHER BRANDS (Low risk for addiction) SOCIAL USE (endurance) PHYSICAL PERFORMANCE (creativity, production inthe workplace) MENTAL PERFORMANCE TARGETED DISORDERS(ie. PTSD) (smoking, alcohol, opiods) ADDICTION (mental healthisvery commonly overlooked) DEPRESSION (high growth segment) ANXIETY Investor Deck2021 12 Psicolcybin Research advanced research anddevelopment, control studies, peerreview registry andasignificant competitive timeline Optimi Health’s application to HealthCanada isunderway andifapproved, paves theway to pilotcultivation, Controlled Substance Research License for Psilocybin Approval anticipated Q22021 (Subject to COVID related delays) advantage towards pharmaceutical industry applications. Investor Deck2021 13 Business Divisions growth formulas andmethods. co-packers usingOptimi functional mushroom • Noextraction markup orloss inwholesalemargin from ofstrains andreduces contamination risk(GMP) • Multipleclimate controlled rooms allows for avariety systems (Argus Controls) • Integrated environmental controls andcultivation areas for maximumyield • Efficient designconfi guration &multiplededicated • Immediate salesofCanadiangrown functionalmushrooms Operational Considerations: Turkey Tail andCordyceps. functional mushroom varieties suchasLion’s Mane, Reishi, Optimi Farms Facility #1isfocused ongrowing highdemand OPTIMI FUNCTIONAL FACILITY ONE: Optimi Farms Investor Deck2021 14 Business Divisions regulatory acceptance ofpsilocybin. • Infrastructure inplace to capitalize onthe increasing Green Pharmaceuticals. purposesthrough acontractual agreement withBC partnershipsestablished inCanadafor medicinal • Pre-existing cannabisconnections to Europe, and programs, clinicaltrials&academicstudies • Opportunityto supplyHealthCanadacertified research shipping,distribution andsales • Onsite product cultivation, extraction, testing, fulfillment, • HealthCanadadealerslicense -pending • HealthCanadaresearch exemption license -approved Operational Considerations: scale medicinal,andpotential wellness market opportunities. containing psilocybin), andisintended to service bothlarge (GMP) offunctionalorpsychoactive mushrooms (i.e. functional mushroom orpharmaceutical grade production Optimi Farms Facility #2isdesignedto accommodate either OPTIMI DEVELOPMENTAL FACILITY TWO: Optimi Farms Investor Deck2021 15 Business Divisions Health Canada. the Company hasreceived aResearch Exemption with products intheCompany’s extended research activities, • The Future ofMushrooms: Inorder to includepsychedelic strategic development partnerships. innovation, OptimiLabsworks withbothacademicand regimens specific to mushroom basedproducts. To expedite compounds, new formulations, testing andprotocol compounds, extraction methods,isolation ofchemical strategy encompassing delivery mechanisms,synthetic • OptimiLabsisdeveloping anintellectual property (IP) formulation research • Pharmaceutical development &new drug • Active compound investigation • Synthetic andnon-synthetic compound exploration • Innovation inhumandelivery mechanisms • Product development • Fungiextract innovation • Improve extraction efficiencies • Improve strain quality&yield • Optimize commercial cultivation processes KEY FUNCTIONS Optimi Labs Investor Deck2021 16 The Functional Opportunity Higher: Brands Net Wellness Formats: to Consume for Ready Popularity Benefits: Health Broad personal optimization. to target a broader customer base willingto invest more in brand vs. amushroom /supplement-only brand allows Optimi recognition for HumanOptimization. Positioned asawellness benefit from vertical integration through Optimibrand name to mushroom orsupplementfocused brands. Optimiaimsto positioned withhigheraverage price perservingcompared The average cost perservingofwellness focused brands are formulating products. to everyday products drive consumer consideration when added, easy consumption methodsthat are complimentary margins whenprocessed into ready-to-consume formats. Value powders). Products soldby Optimiwillachieve significant compared to simple mushroom extract products (e.g. capsules, powders whichallnetahigheraverage revenue perserving Examples includemushroom-enriched coffees /teas /protein brand awareness, andrepeat purchasing interest. efficacy andmessaging designedto instill consumer confidence, combined withpositive customer reviews supportproduct broad range ofbenefits. Ongoingscientifi c andmarket research mushroom strains OptimiFarm aimsto deliver products witha mental wellness (stress resistance). From aselectbaseofkey Functional mushroom benefits range from improved physical to Investor Deck2021 17 Summary of humanoptimization. resources into thefuture capital andprofessional Optimi hasinvested time, and agronomic excellence. to cultivation, processing facilities will bededicated Once operational, these in BritishColumbia. 10,000 sq.ft.facilities of two purpose-built through the construction to launch itsbusiness Optimi Healthispreparing Constructed Facilities Pre-operational into aglobal leader. and aregional business concepts into products, teams aimto nurture it’s world-class advisory house expert research and commercial operations, in- the Company launches mushroom sector. As growing functional targeting therapidly scale operation initially integrated industrial developing avertically opportunities, Optimiis future pharmaceutical and nutraceuticals, to From supplements Consumer -to- Cultivation capable facilites. two purpose-builtGMP mushrooms from its finest strains offunctional package andshipthe cultivate, extract, process, Columbia. Optimiaimsto Princeton, British environmentally conscious business-friendly and Welcome to Located Strategically formulations. into psychoactive advanced research application for of aHealthCanada initiated viasubmission development has been fungi. Future product expanding business of within therapidly the immenseopportunity diversify, andcapitalize on the foundation to scale, Offering diversity and Development Assets in Generating Revenue Multiple Investor Deck2021 18 OPERATIONS DRUG DEVELOPMENT

Company Ticker Market Cultivation/ Clinics/ Functional Research Dealers Phase of Primary Primary Cap Processing Retreats Mushrooms Exemption License Primary Psychedelic Indication ($MM) Clinical Trial Compound

Psychedelics - Drug Development & Functional Mushrooms

COMPASS Pathways plc NasdaqGS:CMPS $2,130.7 X Phase 2B Psilocybin Treatment Resistant Depression (TRD)

Mind Medicine (MindMed) Inc. NEOE:MMED $1,674.0 Phase 2B LSD Anxiety

Cybin Inc. NEOE:CYBN $257.7 Phase 2 Psilocybin Major Depressive Disorder (MDD)

Revive Therapeutics Ltd. CNSX:RVV $171.1 Phase 1 Psilocybin Methamphetamine Use Disorders

Seelos Therapeutics, Inc. NasdaqCM:SEEL $95.8 Phase 1 Ketamine Acute Suicidal Ideation

HAVN Life Sciences Inc. CNSX:HAVN $80.7 X X Pre-Clinical

Mydecine Innovations Group Inc. CNSX:MYCO $81.3 X X X Phase 2A Psilocybin Post-Traumatic Stress Disorder (PTSD)

BetterLife Pharma Inc. CNSX:BETR $96.0 Pre-Clinical LSD

Red Light Holland Corp. CNSX:TRIP $72.4 X

Pure Extracts Technologies Corp. CNSX:PULL $49.4 X X

Mind Cure Health Inc. CNSX:MCUR $39.4 X Pre-Clinical

Entheon Biomedical Corp. CNSX:ENBI $46.2 Phase 1 DMT Addiction and Substace Abuse

Psyched Wellness Ltd. CNSX:PSYC $31.1 X

Better Plant Sciences Inc. CNSX:PLNT $27.0 X

Pharmadrug Inc. CNSX:BUZZ $14.8 Comparable Companies Comparable New Wave Holdings Corp. CNSX:SPOR $15.8 X

Lobe Sciences Ltd. CNSX:LOBE $11.2 Pre-Clinical Psilocybin Post-Traumatic Stress Disorder (PTSD)

Psychedelics - Clinics

Field Trip Health Ltd. CNSX:FTRP $138.7 X Pre-Clinical MDMA Post Traumatic Stress Disorder (PTSD)

Numinus Wellness Inc. TSXV:NUMI $237.4 X X X X Compassionate Access Trial

Champignon Brands Inc. CNSX:SHRM $157.8 X X X Pre-Clinical

Optimi Health Corp. CNSX: OPTI X X X Pending Pre-Clinical Psilocybin Anxiety

Source: S&P Capital IQ, & company fi lings, share price & market cap. data as of January 7, 2021 Investor Deck 2021 19 OPTIMI HEALTH CORP. Canadian Securities Exchange IPO - January 2021

Capitalization Table SHARES CASH PRICE

Founders & Management 20,000,000 $1,000,000

Family & Friends Seed Round 17,963,005 $4,490,751 $0.25

Capitalization Table Table Capitalization Pre IPO 37,963,005 $5,490,751

Warrants

Founders & Management 10,000,000 $1,000,000 $0.10

Family & Friends Seed Round Warrants 17,963,005 $7,185,202 $0.40

Investor Deck 2021 20 OPTIMI HEALTH CORP. Source and Use of Funds

IPO fi nancing - January 2021 We intend to use the existing working capital and net proceeds from the Offering as follows:

Use of Available Funds Estimated Amount Estimated Amount to be Expended to be Expended (Minimum Offering) (Maximum Offering)

Capital expenditures for facilities $6,578,498 $6,578,498

Submission and pursuit of application for research exemption, dealer’s license $450,000 $650,000 and research and development initiatives related to same

Investment in e-commerce business and launch of online platform $1,250,000 $1,750,000

General and Administrative $1,993,934 $1,993,934

Optimi Source & Use of Funds Optimi Source Unallocated working capital $2,276,568 $6,226,568

TOTAL $12,549,000 $17,199,000

Investor Deck 2021 21 THANK YOU

OPTIMI HEALTH CORP. 201 - 1448 Commercial Drive Vancouver BC V5L 3X9

E. [email protected] T. 778 930-1321